MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/24741264261438457

Медицинская библиотека · Journal of vitreoretinal diseases · 2026

Real-World Data on Treatment Compliance and Visual Outcomes Between Patients With Diabetic Macular Edema or Retinal Vein Occlusion Receiving Antivascular Endothelial Growth Factor Injections or Intravitreal Corticosteroid Implants.

Kim Sonia B, Lopez Ana, Gu Xinyu, Reed Hayden, Eppel Priya S, Singh Rishi P, Talcott Katherine E

СтатьяПеревод пока не подготовлен

Аннотация

Purpose: To evaluate real-world differences in treatment frequency, appointment compliance, and visual outcomes among patients with DME or RVO whose eyes either remained on antivascular endothelial growth factor (anti-VEGF) therapy or were transitioned to slow-release intravitreal corticosteroid implants.

Methods

This retrospective cohort study used electronic health records data (2012-2024) from the Cole Eye Institute to identify patients ages ≥18 years diagnosed as having DME or RVO, with included eyes divided into 2 groups: a study group receiving 6 months of anti-VEGF injections followed by 12 months of intravitreal corticosteroid implants, and a control group receiving anti-VEGF injections for the entire 18-month period. Descriptive analysis compared appointment burden and compliance, best-corrected visual acuity (BCVA), and central subfield thickness (CST) between the overall cohort, DME eyes, and RVO eyes.

Results

Ninety-nine eyes (48 study, 51 control) were included. The study group had a higher number of scheduled appointments, despite receiving fewer injections after switching to intravitreal corticosteroid implants. Appointment compliance in the study group remained unchanged before and after switching. Over 18 months, BCVA remained stable, while CST decreased with anti-VEGF therapy but increased after eyes were switched to intravitreal corticosteroid implants.

Conclusions

Although injection frequency was reduced in patients with DME or RVO receiving intravitreal corticosteroid implants, this treatment did not improve appointment compliance and was associated with less favorable anatomic outcomes. Nonetheless, intravitreal corticosteroid implants preserved visual function and may represent a viable alternative for patients with refractory disease or compliance barriers.

Для цитирования: Kim Sonia B, Lopez Ana, Gu Xinyu, Reed Hayden, Eppel Priya S, Singh Rishi P, Talcott Katherine E. Real-World Data on Treatment Compliance and Visual Outcomes Between Patients With Diabetic Macular Edema or Retinal Vein Occlusion Receiving Antivascular Endothelial Growth Factor Injections or Intravitreal Corticosteroid Implants.. Journal of vitreoretinal diseases. 2026. DOI: 10.1177/24741264261438457.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.